FGFR2突变与子宫内膜样子宫内膜癌不良结局相关:一项NRG肿瘤学/妇科肿瘤学组研究
在GOG 210临床试验的973例子宫内膜样子宫内膜癌中,144例存在FGFR2突变,125例为已知激活突变并纳入分析。校正已知预后因素后,FGFR2突变患者无进展生存期(HR 1.903;95% CI 1.177-3.076)和子宫内膜癌特异性生存期(HR 2.013;95% CI 1.096-3.696)显著更短。
要点
- FGFR2激活突变见于约10%的子宫内膜样子宫内膜癌。
- FGFR2突变患者疾病进展(进展、复发或死于疾病)发生率26%(32/125) vs 野生型14%(120/848),p<0.001。
- 校正预后因素后,FGFR2突变与更短的无进展生存期和子宫内膜癌特异性生存期显著相关。
核心结论
- 研究结果提示,有必要开展临床试验评估FGFR抑制剂在辅助治疗中预防复发和死亡的有效性。
研究设计与样本
- 研究为GOG 210临床试验「子宫内膜癌分子分期」的一部分,肿瘤样本经严格病理审查并具有超过三年的详细临床随访。
- 提取DNA并扩增、测序覆盖FGFR2突变热点的四个外显子。
- 973例子宫内膜样子宫内膜癌中鉴定出144例突变,其中125例为已知激活突变并纳入统计分析。
主要发现
- FGFR2突变在初诊III/IV期患者中更常见(29/170;17%) vs I/II期(96/803;12%;p=0.07,卡方检验)。
- FGFR2突变患者疾病进展(进展、复发或死于疾病)发生率显著更高(32/125,26%) vs 野生型(120/848,14%;p<0.001,卡方检验)。
- 校正已知预后因素后,FGFR2突变患者无进展生存期显著更短(HR 1.903;95% CI 1.177-3.076;p<0.025)。
- 校正已知预后因素后,FGFR2突变患者子宫内膜癌特异性生存期显著更短(HR 2.013;95% CI 1.096-3.696;p<0.025)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Activating FGFR2 mutations have been identified in ~10% of endometrioid endometrial cancers (ECs). We have previously reported that mutations in FGFR2 are associated with shorter disease free survival (DFS) in stage I/II EC patients. Here we sought to validate the prognostic importance of FGFR2 mutations in a large, multi-institutional patient cohort. METHODS: Tumors were collected as part of the GOG 210 clinical trial "Molecular Staging of Endometrial Cancer" where samples underwent rigorous pathological review and had more than three years of detailed clinical follow-up. DNA was extracted and four exons encompassing the FGFR2 mutation hotspots were amplified and sequenced. RESULTS: Mutations were identified in 144 of the 973 endometrioid ECs, of which 125 were classified as known activating mutations and were included in the statistical analyses. Consistent with FGFR2 having an association with more aggressive disease, FGFR2 mutations were more common in patients initially diagnosed with stage III/IV EC (29/170;17%) versus stage I/II EC (96/803; 12%; p=0.07, Chi-square test). Additionally, incidence of progression (progressed, recurred or died from disease) was significantly more prevalent (32/125, 26%) among patients with FGFR2 mutation versus wild type (120/848, 14%; p<0.001, Chi-square test). Using Cox regression analysis adjusting for known prognostic factors, patients with FGFR2 mutation had significantly (p<0.025) shorter progression-free survival (PFS; HR 1.903; 95% CI 1.177-3.076) and endometrial cancer specific survival (ECS; HR 2.013; 95% CI 1.096-3.696). CONCLUSION: In summary, our findings suggest that clinical trials testing the efficacy of FGFR inhibitors in the adjuvant setting to prevent recurrence and death are warranted.
引用
- Jeske YW, Ali S, Byron SA, et al. FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017. PMID: 28314589. doi:10.1016/j.ygyno.2017.02.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。